(Abst.) RRMS and PPMS treated w/ocrelizumab: A comparative study on: December 10, 2022, 09:22:01 pm #1 From PubMed (December 10, 2022)--"Relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study": Relapsing-remitting and primary progressive multiple sclerosis treated with ocrelizumab: A comparative study - PubMed Ocrelizumab was very effective in reducing relapses and MRI activity. The rate of progression was slowed down; however, the effect was more evident for pwRRMS than for pwPPMS over time. PubMed · pubmed.ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
